
CNTX Stock Forecast & Price Target
CNTX Analyst Ratings
Bulls say
Context Therapeutics Inc is advancing its pipeline of therapies aimed at treating solid tumors, specifically focusing on female, hormone-dependent cancers, with promising early data emerging from its preclinical program, CTIM-76. The company's strong cash position, which extends into 2027, supports the continued enrollment and evaluation of CTIM-76 across multiple solid tumor types, indicating multiple clinical, regulatory, and data-driven value catalysts in the upcoming year. Furthermore, the early signs of clinical activity and a favorable safety profile for CTIM-76 in heavily pre-treated patients suggest a potential de-risking of the program, which could enhance investor interest and attract potential partnerships prior to the availability of more traditional efficacy data.
Bears say
Context Therapeutics experienced a reduction in research and development expenses in Q3 2025, reporting $8.7 million compared to $16.8 million in the same quarter of the previous year, which may signal a reduction in pipeline advancement or challenges within their clinical programs. Despite this decrease in R&D spending leading to a net loss of $9.7 million—improved from $17.5 million in the previous year—the company is facing significant risks, including the need for approximately $250 million in additional financing through 2041 and potential regulatory hurdles. Furthermore, ongoing concerns regarding safety signals, efficacy levels of their treatments, and competition from existing therapies heighten the uncertainty surrounding the company's future performance and financial stability.
This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.
CNTX Analyst Forecast & Price Prediction
Start investing in CNTX
Order type
Buy in
Order amount
Est. shares
0 shares